microbeПроблемы особо опасных инфекцийProblems of Particularly Dangerous Infections0370-10692658-719XRussian Research Anti-Plague Institute “Microbe”10.21055/0370-1069-2013-2-60-65microbe-34Research ArticleПАТОГЕНЕЗ, ЛЕЧЕНИЕPATHOGENESIS, TREATMENTИспользование мыши в качестве модельного животного для оценки эффективности лечебно-профилактического действия препаратов против оспы обезьянMice as Animal Model for Evaluation of Therapeutic Efficacy of Preparations against MonkeypoxСергеевАл. А.SergeevAl. A.vector@vector.nsc.ruКабановА. С.KabanovA. S.vector@vector.nsc.ruБулычевЛ. Е.BulychevL. E.vector@vector.nsc.ruПьянковО. В.P’YankovO. V.vector@vector.nsc.ruСергеевАр. А.SergeevAr. A.vector@vector.nsc.ruТарановО. С.TaranovO. S.vector@vector.nsc.ruБодневС. А.BodnevS. A.vector@vector.nsc.ruТумановЮ. В.TumanovYu. V.vector@vector.nsc.ruШишкинаЛ. Н.ShishkinaL. N.vector@vector.nsc.ruАгафоновА. П.AgafonovA. P.vector@vector.nsc.ruСергеевА. Н.SergeevA. N.vector@vector.nsc.ruГосударственный научный центр вирусологии и биотехнологии «Вектор»РоссияState Research Centre of Virology and Biotechnology “Vector”Russian Federation201320062013026065Copyright © Сергеев А.А., Кабанов А.С., Булычев Л.Е., Пьянков О.В., Сергеев А.А., Таранов О.С., Боднев С.А., Туманов Ю.В., Шишкина Л.Н., Агафонов А.П., Сергеев А.Н., 20132013Сергеев А.А., Кабанов А.С., Булычев Л.Е., Пьянков О.В., Сергеев А.А., Таранов О.С., Боднев С.А., Туманов Ю.В., Шишкина Л.Н., Агафонов А.П., Сергеев А.Н.Sergeev A.A., Kabanov A.S., Bulychev L.E., P’Yankov O.V., Sergeev A.A., Taranov O.S., Bodnev S.A., Tumanov Y.V., Shishkina L.N., Agafonov A.P., Sergeev A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.microbe.ru/jour/article/view/34

ВОО. Продемонстрирована возможность использования 8–15-суточных мышей ICR (массой 9–11 г) в качестве модельного животного для оценки эффективности лечебно-профилактического действия разрабатываемых препаратов против оспы обезьян и натуральной оспы.

of MPV after 7 days postinfection, applying peroral administration once within 24 hours (24 hours before infection and 7 days after infection of mouse with 60 µg/g of a preparation). Displayed is the feasibility of using 8–15-days-old ICR mice (body weight 9–11 g) as an animal model for evaluation of therapeutic efficacy of the preparations under development against Monkeypox and smallpox.

вирус оспы обезьянмышьинтраназальное инфицирование50 % инфицирующая дозаклинические признакипротивооспенные препаратымодельное животноеMonkeypox virusmouseintranasal infection50 % infective doseclinical signspreparations against Monkeypoxanimal modelReferencesВиноградов И.В., Кочнева Г.В., Малкова Е.М., Щелкунов С.Н., Рябчикова Е.И. Изучение инфекции, вызываемой штаммом ЕР-2 вируса оспы коров у мышей разного возраста. Вопр. вирусол. 2003; 5:34–8.Vinogradov I.V., Kochneva G.V., Malkova E.M., Shchelkunov S.N., Ryabchikova E.I. [Investigations of infection caused by EP-2 vaccinia virus strain in mice of different age]. Vopr. Virusol. 2003; 5:34–8.Виноградов И.В., Кочнева Г.В., Малкова Е.М., Щелкунов С.Н., Рябчикова Е.И. Интраназальная инфекция у мышей, зараженных штаммом ЕР-2 вируса оспы коров, выделенным от слона. Вопр. вирусол. 2005; 4:37–42.Vinogradov I.V., Kochneva G.V., Malkova E.M., Shchelkunov S.N., Ryabchikova E.I. [Intranasal infection in mice, inoculated with EP-2 vaccinia virus strain, isolated from an elephant]. Vopr. Virusol. 2005; 4:37–42.Закс Л. Статистическое оценивание. М.: Статистика; 1976. 598 с.Zaks L. [Statistical Estimation]. M.: Statistics, 1976. 598 p.Руководство по содержанию и использованию лабораторных животных. Перевод с английского. Washington, D.C.: National Akademy Press; 1996. 138 р.National research Council. [Guidelines on Laboratory Animal Care and Use]. Washington: National Academy; 1996.Селиванов Б.А., Беланов Е.Ф., Бормотов Н.И., Балахнин С.М., Серова О.А., Святченко В.А., Киселев Н.Н., Казачинская Е.И., Локтев В.Б., Тихонов А.Я. Производные трицикло[3.2.2.02,4]нон_8_ен_6,7_дикарбоновой кислоты высоко эффективно ингибируют репликацию различных видов ортопоксвирусов. Докл. Акад. наук. 2011; 441(3):414–8.Selivanov B.A., Belanov E.F., Bormotov N.I., Balakhin S.M., Serova O.A., Svyatchenko V.A., Kiselev N.N., Kazachinskaya E.I., Loktev V.B., Tikhonov A.Ya. [Derivatives of the tricycle[3.2.2.02,4]non-8-EN-6,7 dicarboxylic acid inhibit replication of various Orthopoxvirus species to a maximum effect]. Doklady Akademii Nauk. 2011; 441(3):414–18.Chen N., Li G., Liszewski K.M., Atkinson J.P., Jahrling P.B., Feng Z., Schriewer J., Buck C., Wang C., Lefkowitz E.J., Esposito J.J., Harms T., Damon I.K., Roper R.L., Upton C., Buller R.M.L. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin J. Virol. 2005; 340:46–63.Chen N., Li G., Liszewski K.M., Atkinson J.P., Jahrling P.B., Feng Z., Schriewer J., Buck C., Wang C., Lefkowitz E.J., Esposito J.J., Harms T., Damon I.K., Roper R.L., Upton C., Buller R.M.L. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin J. Virol. 2005; 340:46–63.Hutson C.L., Abel J.A., Carroll D.S., Olson V.A., Braden Z.H., Hughes C.M., Dillon M., Hopkins C., Karem K.L., Damon I.K., Osorio J.E. Comparison of West African and Congo Basin monkeypox viruses in BALB/c and C57BL/6 mice. PLoS One. 2009; 5(1):e8912.Hutson C.L., Abel J.A., Carroll D.S., Olson V.A., Braden Z.H., Hughes C.M., Dillon M., Hopkins C., Karem K.L., Damon I.K., Osorio J.E. Comparison of West African and Congo Basin monkeypox viruses in BALB/c and C57BL/6 mice. PLoS One. 2009; 5(1):e8912.Jordan R., Bailey T.R., Rippin S.R. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases. Patent WO 2004/112718 A3; 2005. International Patent Classification C07D 209/56.Jordan R., Bailey T.R., Rippin S.R. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases. Patent WO 2004/112718 A3; 2005. International Patent Classification C07D 209/56.Jordan R., Goff A., Frimm A., Corrado M.L., Hensley L.E., Byrd C.M., Mucker E., Shamblin J., Bolken T.C., Wlazlowski C., Johnson W., Chapman J., Twenhafel N., Tyavanagimatt S., Amantana A., Chinsangaram J., Hruby D.E., Huggins J. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob. Agents Chemother. 2009; 53(5):1817–22.Jordan R., Goff A., Frimm A., Corrado M.L., Hensley L.E., Byrd C.M., Mucker E., Shamblin J., Bolken T.C., Wlazlowski C., Johnson W., Chapman J., Twenhafel N., Tyavanagimatt S., Amantana A., Chinsangaram J., Hruby D.E., Huggins J. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob. Agents Chemother. 2009; 53(5):1817–22.Kochneva G.V., Urmanov I.H., Ryabchikova E.I., Streltsov V.V., Serpintsky O.I. Fine mechanisms of ectromelia virus thymidine kinase-negative mutants avirulence. Virus Res. 1994; 34(1):49–61.Kochneva G.V., Urmanov I.H., Ryabchikova E.I., Streltsov V.V., Serpintsky O.I. Fine mechanisms of ectromelia virus thymidine kinase-negative mutants avirulence. Virus Res. 1994; 34(1):49–61.Leparc-Goffart I., Poirier B., Garin D., Tissier M.-H., Fuchs F., Crance J.-M. Standartization of a neutralizing anti-vaccinia antibodies titration method: an essential step for titration of vaccinia immunoglobulins and smallpox vaccines evaluation. J. Clin. Virol. 2005; 32:47–52.Leparc-Goffart I., Poirier B., Garin D., Tissier M.-H., Fuchs F., Crance J.-M. Standartization of a neutralizing anti-vaccinia antibodies titration method: an essential step for titration of vaccinia immunoglobulins and smallpox vaccines evaluation. J. Clin. Virol. 2005; 32:47–52.Marennikova S.S., Seluhina E.M. Susceptibility of some rodent species to monkeypox virus, and course of the infection. Bull. World Health Organ. 1976; 53:13–20.Marennikova S.S., Seluhina E.M. Susceptibility of some rodent species to monkeypox virus, and course of the infection. Bull. World Health Organ. 1976; 53:13–20.Martinez M.J., Bray M.P., Huggins J.W. A mouse model of aerosol-transmitted orthopoxviral disease: morphology of experimental aerosol-transmitted orthopoxviral disease in a cowpox virus – BALB/c mouse system. Arch. Pathol. Lab. Med. 2000; 124(3):362–77.Martinez M.J., Bray M.P., Huggins J.W. A mouse model of aerosol-transmitted orthopoxviral disease: morphology of experimental aerosoltransmitted orthopoxviral disease in a cowpox virus – BALB/c mouse system. Arch. Pathol. Lab. Med. 2000; 124(3):362–77.Sliva K., Schnierle B. From actually toxic to highly specific – novel drugs against poxviruses. J. Virol. 2007; 4:8.Sliva K., Schnierle B. From actually toxic to highly specific – novel drugs against poxviruses. J. Virol. 2007; 4:8.Stabenow J., Buller R.M., Schriewer J., West C., Sagartz J.E., Parker S.A. Mouse model of lethal infection for evaluating prophylactics and therapeutics against monkeypox virus. J. Virol. 2010; 84(8):3909–20.Stabenow J., Buller R.M., Schriewer J., West C., Sagartz J.E., Parker S.A. Mouse model of lethal infection for evaluating prophylactics and therapeutics against monkeypox virus. J. Virol. 2010; 84(8):3909–20.Zaucha G., Jahrling P., Geisbert T., Swearengen J., Hensley L. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (macaca fascicularis). Lab. Invest. 2001; 81:1581–600.Zaucha G., Jahrling P., Geisbert T., Swearengen J., Hensley L. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (macaca fascicularis). Lab. Invest. 2001; 81:1581–600.

The authors declare that there are no conflicts of interest present.